Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest H5N1 clinical trials Stories

2014-04-02 16:31:07

ROCKVILLE, Md., April 2, 2014 /PRNewswire-USNewswire/ -- Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held March 25 in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria. The awardee, Sanaria® PfSPZ Vaccine, demonstrated complete protection against malaria in all volunteers (6/6) who received high dose immunizations in a...

2014-03-20 16:26:59

DUBLIN, March 20, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/n8dfqv/china_influenza) has announced the addition of the "China Influenza Vaccine Industry Report 2014" [http://www.researchandmarkets.com/research/n8dfqv/china_influenza ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The China Influenza Vaccine Industry Report 2014 is a professional and in-depth study on the...

2014-02-28 14:04:34

Findings May Help Make Immunizations More Effective Somali Americans develop twice the antibody response to rubella from the current vaccine compared to Caucasians in a new Mayo Clinic study on individualized aspects of immune response. A non-Somali, African-American cohort ranked next in immune response, still significantly higher than Caucasians, and Hispanic Americans in the study were least responsive to the vaccine. The findings appear in the journal Vaccine. “This is...

2014-02-26 16:26:54

Study shows vaccine provides protection against EV71-associated hand, foot and mouth disease in infants and young children BEIJING, Feb. 26, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71") vaccine have been published online in the February 27(th) issue of The New England Journal of Medicine ("NEJM"). The clinical results...

2014-01-29 00:20:55

SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent...

2013-11-05 23:24:26

The results show that Colby’s JVRS-100 adjuvant, when used in combination with an influenza virus vaccine, generates enhanced immunity and superior protection of elderly monkeys when challenged with live human flu virus (relative to the vaccine alone). San Jose, CA (PRWEB) November 05, 2013 Colby Pharmaceutical Company (CPC) announces ground-breaking results demonstrating that two inoculations of Colby’s JVRS-100 adjuvant, in combination with Fluzone influenza vaccine, enhance the...

2013-11-05 08:33:30

DORVAL, QC, Nov. 5, 2013 /CNW/ - Newly published data in the medical journal Vaccine shows that FLUAD*, an influenza vaccine indicated specifically for people 65 years and older, provided significantly improved protection against influenza in the elderly in comparison to non-adjuvanted trivalent influenza vaccine in this age group.(1) The investigator-led Canadian study focused on British Columbia with seniors who are at an increased risk of influenza or pneumonia and who suffer...

2013-11-04 08:26:49

Solutions company to improve the efficacy of public health and bioterror countermeasures by developing, manufacturing, applying and testing a novel adjuvant for West Nile virus and anthrax vaccine candidates. RESTON, Va., Nov. 4, 2013 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, announced it has been awarded a prime vaccine adjuvant development contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of...

2013-09-26 16:27:33

BALTIMORE, Sept. 26, 2013 /PRNewswire-USNewswire/ -- The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has successfully competed for and received a renewed contract to conduct basic research and clinical studies of vaccines, diagnostics, and therapeutics. Support for this work to combat existing and emerging infectious diseases is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health...

2013-08-26 08:27:55

- Efficacy trial in more than 30,000 older adults meets primary endpoint for superior efficacy - LYON, France, Aug. 26, 2013 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone(®) High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing...